Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (42814)	4/12/2000 2:33:00 PM
From: Taki	Read Replies (1) \| Respond to of 150070

MDCH, moving back up due to this news out today. (COMTEX) B: MEDITECH PHARMACEUTICALS INC - Initial MTCH-24 Trials Yie B: MEDITECH PHARMACEUTICALS INC - Initial MTCH-24 Trials Yield Positive Results New York, New York, Apr. 12, 2000 (Market News Publishing via COMTEX) -- Meditech Pharmaceuticals Inc. announced that Immune Network Research Ltd. has confirmed that scientific studies which are ongoing with MTCH-24 have yielded positive results. Preliminary toxicity tests contracted by Immune Network indicate that MTCH-24 has a more favorable profile than other compounds in the same chemical class. These studies are the first of a series of laboratory studies that have already been contracted by Immune Network. Further tests underway with MTCH-24 will investigate its mode of action. Clinical studies are also being planned to support Meditech's marketing efforts. Meditech Chief Executive Officer Gerald Kern has also indicated that, "Plans have been formulated for marketing the soon to be commercially renamed MTCH-24 immediately upon completion of OTC clinical studies. Renaming, package and label development have begun and will be ready by the time the tests are completed. "Having spent most of my business life as a senior sales and marketing executive with major consumer products companies, I welcome the opportunity to begin marketing Meditech's products." Kern said that marketing plans will include conventional retail channels, but will also take advantage of Internet/e-commerce sales opportunities for the initial products. The company has also engaged the services of a consultant in the State of Florida to pursue possibilities for its proposed Citrus Canker product. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this release that are not historical facts are forward-looking statements subject to risks and uncertainties which could cause actual results to differ materially from those set forth in or implied by forward-looking statements. These risks are described in detail in the company's Securities and Exchange Commission filings. __________________________________________________ ___________________________________________________________________ (c) Market News Publishing Inc. Tel:(604) 689-1101 All rights reserved. Fax:(604) 689-1106 MarketbyFax(tm) - To get the NEWS as it happens, call (604) 689-3041. -0- * end of story * (COMTEX) B: MEDITECH PHARMACEUTICALS INC - Initial MTCH-24 Trials Yie B: MEDITECH PHARMACEUTICALS INC - Initial MTCH-24 Trials Yield Positive Results New York, New York, Apr. 12, 2000 (Market News Publishing via COMTEX) -- Meditech Pharmaceuticals Inc. announced that Immune Network Research Ltd. has confirmed that scientific studies which are ongoing with MTCH-24 have yielded positive results. Preliminary toxicity tests contracted by Immune Network indicate that MTCH-24 has a more favorable profile than other compounds in the same chemical class. These studies are the first of a series of laboratory studies that have already been contracted by Immune Network. Further tests underway with MTCH-24 will investigate its mode of action. Clinical studies are also being planned to support Meditech's marketing efforts. Meditech Chief Executive Officer Gerald Kern has also indicated that, "Plans have been formulated for marketing the soon to be commercially renamed MTCH-24 immediately upon completion of OTC clinical studies. Renaming, package and label development have begun and will be ready by the time the tests are completed. "Having spent most of my business life as a senior sales and marketing executive with major consumer products companies, I welcome the opportunity to begin marketing Meditech's products." Kern said that marketing plans will include conventional retail channels, but will also take advantage of Internet/e-commerce sales opportunities for the initial products. The company has also engaged the services of a consultant in the State of Florida to pursue possibilities for its proposed Citrus Canker product. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this release that are not historical facts are forward-looking statements subject to risks and uncertainties which could cause actual results to differ materially from those set forth in or implied by forward-looking statements. These risks are described in detail in the company's Securities and Exchange Commission filings. __________________________________________________ ___________________________________________________________________ (c) Market News Publishing Inc. Tel:(604) 689-1101 All rights reserved. Fax:(604) 689-1106 MarketbyFax(tm) - To get the NEWS as it happens, call (604) 689-3041. -0-